Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208887 | 0.88 | MIF (0.37) | MIFEPHX1HPGDSMN1; SMN2GAA | |
| SCHEMBL938718 | 0.84 | EPHX1 (0.37) | MIFEPHX1PKMTAAR1SLC6A2 | |
| SCHEMBL3748652 | 0.84 | TRPA1 (0.40) | MIFEPHX1HPGDSMN1; SMN2PKM | |
| SCHEMBL300073 | 0.83 | EPHX1 (0.35) | MIFEPHX1PKMTAAR1SLC6A2 | |
| Hydrochloric Acid SCHEMBL3569025 | 0.83 | EPHX1 (0.36) | MIFEPHX1PKMTAAR1SLC6A2 | |
| SCHEMBL1430902 | 0.80 | MIF (0.56) | MIFHPGDSMN1; SMN2GAAPKM | |
| SCHEMBL8249227 | 0.80 | ESR1 (0.39) | MIFEPHX1SMN1; SMN2L3MBTL1 | |
| SCHEMBL3558393 | 0.80 | MIF (0.36) | MIFEPHX1HPGDSMN1; SMN2GAA | |
| SCHEMBL506238 | 0.78 | LMNA (0.37) | EPHX1PKMTAAR1SLC6A2MAOA | |
| SCHEMBL15547346 | 0.78 | MTNR1A (0.43) | MIFHPGDSMN1; SMN2GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716160-B1 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-29 | — | — | EP | claimed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | claimed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | claimed |
| JP-2007518807-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1716160-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | EP | claimed |
| US-20050176769-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | claimed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | claimed |
| US-8546358-B2 | Method of treating asthma | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-01 | — | — | US | disclosed |
| US-20130131401-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-05-23 | — | — | US | disclosed |
| US-8378122-B2 | Process for the preparation of chymase modulators | JANSSEN PHARMACEUTICA NV. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120309986-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | ANZALONE LUIGI (US) | 2012-12-06 | — | — | US | disclosed |
| US-8263785-B2 | Process for the preparation of chymase modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | HAWKINS MICHAEL J (US) | 2012-01-26 | — | — | US | disclosed |
| US-20090036409-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2009-02-05 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
| US-20080096844-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
| WO-2008048668-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-24 | — | — | WO | disclosed |
| EP-1716160-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-02 | — | — | EP | disclosed |
| US-20050176769-A1 | Novel inhibitors of chymase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | US | disclosed |
| WO-2005073214-A2 | NOVEL INHIBITORS OF CHYMASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096844-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, PRSS1 | MIF 424/4885EPHX1 468/4885HPGD 1141/4885 |
| US-20050176769-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | MIF 497/4885EPHX1 308/4885HPGD 849/4885 |
| US-20090036409-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | MIF 497/4885EPHX1 308/4885HPGD 849/4885 |
| US-20120022022-A1 | NOVEL INHIBITORS OF CHYMASE | CMA1, SERPINB1, TPSAB1 | MIF 497/4885EPHX1 308/4885HPGD 849/4885 |
| US-20130131401-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | CMA1, SERPINB1, CPA3 | MIF 585/4885EPHX1 749/4885HPGD 962/4885 |
| US-20120309986-A1 | PROCESS FOR THE PREPARATION OF CHYMASE MODULATORS | CMA1, SERPINB1, CPA3 | MIF 585/4885EPHX1 749/4885HPGD 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.